Neuphoria Therapeutics, Inc. (NEUP)
3.73
0.00 (0.00%)
USD |
NASDAQ |
Sep 11, 16:00
3.74
+0.01
(+0.27%)
After-Hours: 20:00
Neuphoria Therapeutics Enterprise Value : 0.6508M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 0.6508M |
| September 10, 2026 | 0.6508M |
| September 09, 2026 | 0.7584M |
| September 08, 2026 | 0.7584M |
| September 04, 2026 | 0.8659M |
| September 03, 2026 | 0.8121M |
| September 02, 2026 | 0.7584M |
| September 01, 2026 | 0.9735M |
| August 31, 2026 | 0.8121M |
| August 28, 2026 | 0.8121M |
| August 27, 2026 | 0.8659M |
| August 26, 2026 | 1.350M |
| August 25, 2026 | 1.350M |
| August 24, 2026 | 1.834M |
| August 21, 2026 | 1.619M |
| August 20, 2026 | 1.834M |
| August 19, 2026 | 1.726M |
| August 18, 2026 | 1.995M |
| August 17, 2026 | 1.296M |
| August 14, 2026 | 1.404M |
| August 13, 2026 | 1.189M |
| August 12, 2026 | 1.081M |
| August 11, 2026 | 1.081M |
| August 10, 2026 | 1.350M |
| August 07, 2026 | 1.135M |
| Date | Value |
|---|---|
| August 06, 2026 | 1.565M |
| August 05, 2026 | 1.834M |
| August 04, 2026 | 1.511M |
| August 03, 2026 | 1.726M |
| July 31, 2026 | 1.457M |
| July 30, 2026 | 1.672M |
| July 29, 2026 | 1.027M |
| July 28, 2026 | 1.081M |
| July 27, 2026 | 1.296M |
| July 24, 2026 | 0.1669M |
| July 23, 2026 | 1.672M |
| July 22, 2026 | -1.500M |
| July 21, 2026 | -1.446M |
| July 20, 2026 | -1.661M |
| July 17, 2026 | -1.043M |
| July 16, 2026 | -0.4246M |
| July 15, 2026 | -0.4784M |
| July 14, 2026 | -0.2095M |
| July 13, 2026 | -0.6397M |
| July 10, 2026 | -0.3709M |
| July 09, 2026 | -0.5322M |
| July 08, 2026 | -0.4784M |
| July 07, 2026 | -0.102M |
| July 06, 2026 | -0.9086M |
| July 02, 2026 | -1.231M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 560.41M |
| Amgen, Inc. | 247.31B |
| Anika Therapeutics, Inc. | 266.01M |
| BioCryst Pharmaceuticals, Inc. | 2.556B |
| Imunon, Inc. | 7.840M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.5051M |
| Total Expenses (Quarterly) | 0.5051M |
| EPS Diluted (Quarterly) | -0.0933 |
| Earnings Yield | 34.12% |
| Operating Earnings Yield | 17.96% |
| Normalized Earnings Yield | 62.77 |